Last reviewed · How we verify
Placebo ointment daily for 24 month
Placebo ointment daily for 24 month is a Small molecule drug developed by University of Toronto. It is currently in Phase 3 development for Placebo-controlled trial for 24 months.
This drug has no known mechanism of action as it is a placebo.
This drug has no known mechanism of action as it is a placebo. Used for Placebo-controlled trial for 24 months.
At a glance
| Generic name | Placebo ointment daily for 24 month |
|---|---|
| Sponsor | University of Toronto |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo is a substance or treatment that has no therapeutic effect, used as a control in clinical trials to compare the effectiveness of a real treatment. In this case, the placebo ointment is applied daily for 24 months, but it does not have any active ingredients that would produce a biological effect.
Approved indications
- Placebo-controlled trial for 24 months
Common side effects
Key clinical trials
- Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC (PHASE3)
- Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current (PHASE2, PHASE3)
- The Nitrate and Bone Study: Effects of Nitrates on Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo ointment daily for 24 month CI brief — competitive landscape report
- Placebo ointment daily for 24 month updates RSS · CI watch RSS
- University of Toronto portfolio CI